The growth of Viagra and its impact on the drug landscape presents a complex question for shareholders. While the first sales data were astounding, the intellectual property has lapsed, leading to a wave of generic alternatives that are eroding revenue. Moreover, the market is facing issues related to aging trends and changing read more healthcare